CAESAREA, Israel, Aug. 25, 2015 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced that in conjunction with its Australian distributor, uHealth, the Company is exhibiting at the Australian Diabetes Society (ADS) and Australian Diabetes Educators Association's (ADEA) 2015 Annual Scientific Meeting and Exhibition in Adelaide, Australia. From Wednesday, August 26th through Friday, August 28th, at Booth #9 LabStyle will showcase the Dario Diabetes Management System. The Dario platform is a next generation technology that digitizes every testing event through a miniature meter powered directly by a smartphone via the audio jack turning an iOs or Android smartphone into a cloud-linked meter. In addition to having received regulatory approval in Australia, the Dario is CE marked in Europe and approved in Canada.
The ADS/ADEA meeting will bring together national and international experts to promote the exchange of the latest clinical practices and cutting edge research in diabetes through state-of-the-art lectures, free communication sessions and clinical and scientific educational symposia.
"This is an ideal forum to showcase the Dario to diabetes educators who work with patients daily to help them improve their quality of life. The Dario offers a new paradigm in disease management by engaging users to maintain therapy adherence, while giving real time notification to caregivers through a coaching platform for physicians and institutions," stated Erez Raphael, LabStyle's Chairman and Chief Executive Officer. "uHealth has been a very good partner for us in the Australian market, where an estimated 1.2 million people with diabetes can benefit from the Dario."
The Dario was recently featured on 9News Australia. To view the news segment in full please visit: https://www.youtube.com/watch?v=dIPVyZxwlw8
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario™ personalized smart meter. Dario™ received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario™ Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: www.mydario.com and http://mydario.investorroom.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/labstyle-innovations-to-exhibit-at-australian-diabetes-societys-annual-meeting-on-august-26--28-2015-300132801.html
SOURCE LabStyle Innovations Corp.